Biocryst Pharmaceuticals INC Form 4 insider transactions

Director Vincent Milano acquired 653 shares of BioCryst Pharmaceuticals common stock on February 28, 2025, in lieu of 50% of his quarterly cash board member retainer.

Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals, reports acquisition of restricted stock units and employee stock options, as well as shares withheld for tax obligations.

Helen M. Thackray, Chief R&D Officer of BioCryst Pharmaceuticals, reports acquisition of stock options and restricted stock units, along with shares withheld for tax obligations.

Anthony Doyle, CFO of BioCryst Pharmaceuticals, reports acquisition and disposal of common stock and stock options.

Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals, reports acquisition of restricted stock units and employee stock options, as well as shares withheld for tax obligations.

Jon P. Stonehouse, President and CEO of BioCryst Pharmaceuticals, reports acquisition and disposal of company stock and derivative securities.

BioCryst Pharmaceuticals' Chief Commercial Officer, Charles K. Gayer, sold 8,251 shares to cover tax obligations related to vesting restricted stock units.

BioCryst Pharmaceuticals CEO, Jon P. Stonehouse, disposed of 27,525 shares to cover tax obligations related to vesting restricted stock units.

Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals, had shares withheld to cover tax obligations related to vesting restricted stock units.

BioCryst Pharmaceuticals' Chief Financial Officer, Anthony Doyle, sold 7,890 shares to cover tax obligations related to vesting restricted stock units.

BioCryst Pharmaceuticals' Chief R&D Officer, Helen M. Thackray, sold 7,150 shares to cover tax obligations related to vesting restricted stock units.

A BioCryst Pharmaceuticals director, Nancy J. Hutson, sold 7,000 shares of common stock to cover tax liabilities related to vesting restricted stock units.

Director Vincent Milano acquired 750 shares of BioCryst Pharmaceuticals common stock in lieu of a portion of his quarterly cash retainer.

Director Vincent Milano acquired 647 shares of BioCryst Pharmaceuticals common stock at $8.69 per share in lieu of a portion of his quarterly board member retainer.

Amy E. McKee, a director at BioCryst Pharmaceuticals, sold 8,600 shares of common stock on June 24, 2024, to cover tax liabilities related to the vesting of restricted stock units.

Machelle Sanders, a director at BioCryst Pharmaceuticals, sold 4,689 shares of common stock on June 17, 2024, to cover tax liabilities related to the vesting of restricted stock units.

Machelle Sanders, a director at BioCryst Pharmaceuticals, received stock options and restricted stock units as part of the company's Non-Employee Director Compensation Policy.

Director Vincent Milano reported the acquisition of common stock and stock options from BioCryst Pharmaceuticals on June 12, 2024, as part of a non-employee director compensation policy.

Director Amy E. McKee reported the acquisition of restricted stock units and stock options in BioCryst Pharmaceuticals, according to a Form 4 filing.

Director Alan G. Levin reports the acquisition of restricted stock units and stock options in BioCryst Pharmaceuticals as part of a non-employee director compensation policy.

Nancy J. Hutson, a director at BioCryst Pharmaceuticals, reported the acquisition of restricted stock units and stock options on June 12, 2024, as part of the company's non-employee director compensation policy.

Director Theresa Heggie reports acquisition of restricted stock units and stock options, along with a sale of common stock to cover tax obligations.

Director Steven K. Galson reports acquisition of restricted stock units and stock options in BioCryst Pharmaceuticals.

Director Steve Aselage received stock options and restricted stock units from BioCryst Pharmaceuticals on June 12, 2024.

Director George B. Abercrombie reports acquisition of BioCryst Pharmaceuticals stock and options via automatic non-employee director grants.

Director Theresa Heggie acquired 870 shares of BioCryst Pharmaceuticals common stock on May 31, 2024, in lieu of a portion of her quarterly board member retainer.

Director Vincent Milano acquired 870 shares of BioCryst Pharmaceuticals common stock on May 31, 2024, in lieu of a portion of his quarterly board member retainer.

Director Alan G. Levin of BioCryst Pharmaceuticals Inc. reports the acquisition of 7,861 shares of common stock at $6.36 per share on May 30, 2024.

Director Steve Aselage purchased 2,500 shares of BioCryst Pharmaceuticals at $6.40 per share on May 24, 2024.

Director Nancy J. Hutson increased her holdings in BioCryst Pharmaceuticals by purchasing 5,000 shares of common stock at an average price of $6.38 on May 20, 2024.